Tag #Elevidys

Showing 1 to 1 of 1 results

forbes.com
🌐 75% Global Worthiness
News related image

Sarepta Stock Surges After FDA Lifts Hold on Elevidys

Following the FDA's decision to lift the clinical hold on its Elevidys drug, Sarepta Therapeutics' stock price rose to approximately $19 in extended trading, driven by increased revenue potential and a company restructuring plan aiming for $400 million in annual cost savings by 2026.

Progress

44% Bias Score

Good Health and Well-being

Showing 1 to 1 of 1 results